RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - June 02, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company dedicated to solving problems for patients with cancer, announced today updated results from its ongoing Phase I/II study of ADH-1 in combination with isolated limb infusion melphalan for the treatment of melanoma which were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. ADH-1 is a novel peptide which targets N-cadherin mediated cell adhesion being developed by Adherex to enhance the cytotoxic effects of chemotherapy.
